Department of Oncology, The First Affiliated Hospital of Zhengzhou University, China; Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Leuk Res. 2022 Jul;118:106881. doi: 10.1016/j.leukres.2022.106881. Epub 2022 Jun 2.
To explore the best treatment for early natural killer/T (NK/T)-cell lymphoma, we compared the efficacy and safety of DDGP (pegaspargase, gemcitabine, cisplatin and dexamethasone) followed by radiotherapy (RT) and VIPD (etoposide, ifosfamide, cisplatin, and dexamethasone) followed by radiotherapy for newly diagnosed patients.
40 newly diagnosed patients with stage I-II from January 2011 to November 2016 were treated with DDGP followed by radiotherapy or VIPD followed by radiotherapy. They were assessed in this study.
The complete response rate (CRR) and overall response rate (ORR) of the DDGP followed by radiotherapy group were higher than those of the VIPD followed by radiotherapy group (CRR: 85 % vs 50 %, P = 0.018; ORR: 95 % vs 65 %, P = 0.048). The 5-year progression-free survival (PFS) rate was better in the DDGP followed by radiotherapy group (83.3 % vs 44.4 %, χ2 = 7.809, P = 0.005). There was no significant difference in the 5-year overall survival (OS) rate between the two groups (83.0 % vs 72.1 %, χ2 = 0.231, P = 0.631). Treatment method (P = 0.011) and IPI score (P = 0.027) were independent risk factors for PFS. The DDGP followed by radiotherapy group was more prone to grade I-II clotting dysfunction (P = 0.004).
In patients newly diagnosed with early NK/T-cell lymphoma, those treated with DDGP followed by radiotherapy had a higher CRR and ORR and longer PFS than those treated with VIPD followed by radiotherapy, and adverse reactions were tolerable.
为了探索早期自然杀伤/T（NK/T）细胞淋巴瘤的最佳治疗方法，我们比较了 DDGP（培门冬酶、吉西他滨、顺铂和地塞米松）联合放疗与 VIPD（依托泊苷、异环磷酰胺、顺铂和地塞米松）联合放疗治疗初诊患者的疗效和安全性。
2011 年 1 月至 2016 年 11 月，40 例Ⅰ-Ⅱ期初诊患者分别接受 DDGP 联合放疗或 VIPD 联合放疗。本研究对其进行了评估。
DDGP 联合放疗组的完全缓解率（CRR）和总缓解率（ORR）均高于 VIPD 联合放疗组（CRR：85% vs 50%，P=0.018；ORR：95% vs 65%，P=0.048）。DDGP 联合放疗组 5 年无进展生存率（PFS）更好（83.3% vs 44.4%，χ2=7.809，P=0.005）。两组 5 年总生存率（OS）率无显著差异（83.0% vs 72.1%，χ2=0.231，P=0.631）。治疗方法（P=0.011）和国际预后指数（IPI）评分（P=0.027）是 PFS 的独立危险因素。DDGP 联合放疗组更易发生Ⅰ-Ⅱ级凝血功能障碍（P=0.004）。
对于初诊早期 NK/T 细胞淋巴瘤患者，DDGP 联合放疗的 CRR 和 ORR 更高，PFS 更长，不良反应可耐受。
